View video here: Link
CAMBRIDGE, Mass., July 6, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq:NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the Company's clinical and operational developments during the second quarter of 2023.
Read more at prnewswire.com